Cohen & Steers (CNS) Q2 2025 Earnings
How Did CNS Stock React to Q2 2025 Earnings?
S&P 500 over the same 30 days: +1.95%.
Did CNS Beat Earnings? Q2 2025 Results
No. Cohen & Steers reported Q2 2025 earnings of $0.73 a share on Jul 17, 2025, missing the $0.76 consensus estimate by 3.3%. Revenue was $136.1M against a $135.5M estimate.
Cohen & Steers delivered a mixed second quarter for 2025, posting adjusted diluted EPS of $0.73 against a consensus estimate of $0.76, a miss of 3.31%, even as revenue of $136.13 million edged past expectations by 0.47% and climbed 7.4% year-over-year. The earnings shortfall traced primarily to a surge in operating expenses, which rose 4.0% sequentially to $92.80 million, well ahead of the 1.2% quarter-over-quarter revenue gain, compressing adjusted operating margin by 180 basis points to 33.6%. Higher compensation costs, including accelerated restricted stock vesting tied to employee retirements, along with elevated talent acquisition and business development spending, were the key culprits. Assets under management climbed 10.2% from a year ago to $88.94 billion, supported by $2.25 billion in market appreciation, though net outflows of $131.00 million partially tempered the gain. Preferred securities strategies saw the sharpest redemption pressure, with $480.00 million in net outflows, while global listed infrastructure AUM grew 19.0% year-over-year to $10.05 billion, signaling continued investor appetite for that strategy.
- Higher average assets under management in open-end funds and institutional accounts
- One additional calendar day in Q2 2025 versus Q1 2025
- Market appreciation of $2.3 billion driving AUM growth
- Strong year-over-year AUM growth of 10.2%
- Net inflows of $397 million into U.S. real estate open-end funds
- Global listed infrastructure AUM up 19.0% year-over-year
CNS YoY Financials
| Metric | Q2 2025 | Q2 2024 | Year over year |
|---|---|---|---|
| Revenue | $136.1M | $126.8M | +7.4% |
| Operating Income | $43.3M | $38.4M | +12.8% |
| Net Income | $36.8M | $31.8M | +16.0% |
CNS Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.